Neuroimmunology targets in neurodegeneration are hotter than ever. Capturing biopharma’s latest research spanning discovery to early clinical development, the 6th Neuroimmunology Drug Development Summit is the industry-choice, comprehensive forum dedicated to translating neuroinflammatory-targeted therapeutics into clinical trials.

What are the top features to look forward to in 2024?

• Doubled pre-conference workshop content, with 6 deep-dive sessions tailored to your discovery biology and translational expertise led by neuroimmunology leaders from Lundbeck, Sanofi, Merck, Regeneron, and more
• Agenda content spotlighted neurodegeneration – including TREM2 clinical data updates and breaking down trial design and rationale with Alector and Vigil Neuroscience
• New case studies beyond microglia, with sessions spearheading astrocyte function and therapeutic intervention from Sanofi, IMNEWRUN, and UCL
• Brand-new content on immunocompetent brain organoids to recapitulate and investigate complex neuroimmune interactions with Roche and Herophilus
• It is the biggest and most comprehensive program to date, with 38+ industry and academic speakers, including new presenting companies Eisai, EMD Serono, Ventus Therapeutics, PTC Therapeutics, and Inflammasome Therapeutics

Uniting 100+ all-star leaders across industry and academia, this is the must-attend forum for anyone working on treatments targeting neuroinflammation across neurological indications and looking to accelerate their candidates into the clinic in 2024.

To know more visit: https://ter.li/wb3bhh